Role Description

We are seeking a Senior Scientist to join our team in a full-time role. The Senior Scientist will work as part of a small team to deploy our platform to enable drug discovery for gene regulators. We are looking for a scientific leader interested in solving complex biological problems in a fast-paced, innovative, early-stage biotech environment.


  • Design and execution of experiments to discover, validate and understand the mechanism of action for small molecule therapeutics
  • Design, execution, and analysis of genomics, epigenomics and/or transcriptomics experiments
  • Build and conduct assays that answer key underlying mechanistic questions and activity of Talus' molecules, including genome engineering of human cancer cell lines
  • Conduct independent research and demonstrate scientific leadership within the project team and across departments; Collaborate with all the functions within and outside of Talus to advance our science
  • Accurately document experiments and results in electronic laboratory notebooks in a timely fashion
  • Maintain a safe and productive laboratory environment
  • Prepare and present experimental results, analysis, and plans in R&D meetings



  • The successful candidate will have a PhD with 0-3 or BS/MS degree with 5-7 years of industry experience in pharmaceutical development
  • Familiarity with biochemical and cell-based assay development
  • Familiarity with modern sequencing-based assays including ChIP-seq, ATAC-seq and RNA-seq
  • Strong skills in statistics and data analysis using bioinformatics software including R and/or Python
  • Ability to deliver complex results to teams of diverse scientific backgrounds
  • Ability to work effectively and collaboratively on cross-functional projects teams
  • Excellent oral, presentation, and written communication skills


  • Experience working with shotgun proteomics data
  • Experience with CRISPR or related genome-editing technologies
  • Deep familiarity with cancer biology
  • Experience working in small teams and managing contract research organizations (CROs)

About Talus Bio

Therapeutic development is on the verge of a revolution. The tools of genome sequencing have helped us discover which proteins are best to target across countless diseases. The problem is that most of these top-tier targets have been written off as undruggable because they don't fit into the "standard" experimental models developed by the pharmaceutical industry. Fundamental breakthroughs in proteomics technology being developed at Talus will allow us to unlock many of these targets for the first time.

Talus Bio's vision is to build a tech-bio therapeutics engine that will unlock the genome regulatory network (the "regulome") for systematic drug development. The regulome is responsible for interpreting the human genome by switching genes on and off at the correct time in the correct cells, and their malfunction is common across many diseases. Currently, less than 20 regulome targets have been drugged, leaving over 400 targets left to be addressed in cancer alone.

Our platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for hundreds of gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.

The science on which the company was founded was developed at the Altius Institute for Biomedical Research and the University of Washington in Seattle. The initial work was published in Cell Reports in 2020- and further written up in FierceBiotech. Talus Bio's investors include leading venture funds (including NFX, Fifty Years, FundersClub, Pioneer Fund, Axial, Boom Capital, and others), as well as grant support from the National Science Foundation.